Advantagene's Series A Round

Advantagene raised a round of funding on April 20, 2016. Investors include National Securities Corporation.

Advantagene is a Boston-area privately held biopharmaceutical company focused on preventing the recurrence and progression of cancer through the use of novel therapeutics in oncology and immunotherapy…

Articles about Advantagene's Series A Round: